Cancer Epidemiology and Cancer Services Research, Sydney School of Public Health, Sydney, Australia; Surgical Outcomes Research Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Br J Surg. 2014 Feb;101(3):277-87. doi: 10.1002/bjs.9392. Epub 2014 Jan 13.
Pelvic exenteration is highly radical surgery offering the only potential cure for locally advanced pelvic cancer. This study compared quality of life and other relevant patient-reported outcomes over 12 months for patients who did and those who did not undergo pelvic exenteration.
Consecutive patients referred for consideration of pelvic exenteration completed clinical and patient-reported outcome assessments at baseline, hospital discharge (exenteration patients only), and 1, 3, 6, 9 and 12 months. Outcomes included cancer-specific quality of life (Functional Assessment of Cancer Therapy - Colorectal; FACT-C), physical and mental health status (Short Form 36 version 2), psychological distress (Distress Thermometer), and pain (study-specific composite) scores. Linear mixed modelling compared trajectories between exenteration and no-exenteration groups.
Among 182 patients, 148 (81.3 per cent) proceeded to exenteration. There were no baseline differences between the two groups. Among patients who had exenteration, the mean FACT-C score at baseline of 93.0 had reduced by 14·4 points at hospital discharge, but increased to 86·7 at 1 month after surgery and continued to improve, returning to baseline by 9 months. For patients in the no-exenteration group, FACT-C scores decreased between baseline and 1 month, increased slowly to 6 months and then began to decline at 9 months. There were few statistically or clinically significant differences in any patient-reported outcomes between the groups.
Quality of life and related patient-reported outcomes improve rapidly after pelvic exenteration surgery. For 9 months after surgery, these outcomes are comparable with those of similar do patients who do not have surgery; thereafter, there is a decline in patients who do not have exenteration. Pelvic exenteration can be performed with acceptable quality of life and patient-reported outcomes.
盆腔廓清术是一种高度激进的手术,为局部晚期盆腔癌提供了唯一潜在的治愈机会。本研究比较了接受和未接受盆腔廓清术的患者在 12 个月内的生活质量和其他相关患者报告结果。
连续转诊接受盆腔廓清术评估的患者在基线、出院(仅廓清术患者)以及 1、3、6、9 和 12 个月时完成临床和患者报告结果评估。结果包括癌症特异性生活质量(癌症治疗功能评估-结直肠癌;FACT-C)、身体和心理健康状况(SF-36 版本 2)、心理困扰(困扰温度计)和疼痛(研究特异性综合)评分。线性混合模型比较了廓清术组和非廓清术组之间的轨迹。
在 182 名患者中,148 名(81.3%)接受了廓清术。两组在基线时没有差异。在接受廓清术的患者中,基线时的 FACT-C 评分 93.0 分,出院时降低了 14.4 分,但在手术后 1 个月时增加到 86.7 分,并继续改善,在 9 个月时恢复到基线。对于未接受廓清术的患者,FACT-C 评分在基线至 1 个月期间下降,缓慢增加至 6 个月,然后在 9 个月时开始下降。两组在任何患者报告结果方面差异均无统计学意义或临床意义。
盆腔廓清术后生活质量和相关患者报告结果迅速改善。手术后 9 个月,这些结果与未接受手术的类似患者相似;此后,未接受廓清术的患者结果下降。盆腔廓清术可以获得可接受的生活质量和患者报告结果。